Immunovia AB (publ) (STO:IMMNOV)

Immunovia AB Statistics

Total Valuation

Immunovia AB has a market cap or net worth of SEK 137.22 million. The enterprise value is 81.14 million.

Market Cap	137.22M
Enterprise Value	81.14M

Important Dates

The last earnings date was Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

Immunovia AB has 672.67 million shares outstanding. The number of shares has increased by 243.45% in one year.

Current Share Class	672.67M
Shares Outstanding	672.67M
Shares Change (YoY)	+243.45%
Shares Change (QoQ)	+27.11%
Owned by Insiders (%)	9.70%
Owned by Institutions (%)	13.80%
Float	607.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	151.13
PB Ratio	2.95
P/TBV Ratio	3.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.76
EV / Sales	89.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.05

Current Ratio	3.05
Quick Ratio	3.04
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -281.30% and return on invested capital (ROIC) is -131.77%.

Return on Equity (ROE)	-281.30%
Return on Assets (ROA)	-91.31%
Return on Invested Capital (ROIC)	-131.77%
Return on Capital Employed (ROCE)	-171.99%
Weighted Average Cost of Capital (WACC)	18.88%
Revenue Per Employee	69,846
Profits Per Employee	-8.20M
Employee Count	13
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.52% in the last 52 weeks. The beta is 2.66, so Immunovia AB's price volatility has been higher than the market average.

Beta (5Y)	2.66
52-Week Price Change	-47.52%
50-Day Moving Average	0.20
200-Day Moving Average	0.30
Relative Strength Index (RSI)	49.72
Average Volume (20 Days)	6,162,711

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Immunovia AB had revenue of SEK 908,000 and -106.56 million in losses. Loss per share was -0.24.

Revenue	908,000
Gross Profit	629,000
Operating Income	-79.98M
Pretax Income	-106.56M
Net Income	-106.56M
EBITDA	-80.81M
EBIT	-79.98M
Loss Per Share	-0.24

Balance Sheet

The company has 56.09 million in cash and n/a in debt, with a net cash position of 56.09 million or 0.08 per share.

Cash & Cash Equivalents	56.09M
Total Debt	n/a
Net Cash	56.09M
Net Cash Per Share	0.08
Equity (Book Value)	46.50M
Book Value Per Share	0.07
Working Capital	39.32M

Cash Flow

Operating Cash Flow	-74.93M
Capital Expenditures	n/a
Depreciation & Amortization	-831,500
Net Borrowing	-1.01M
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	69.27%
Operating Margin	-8,808.37%
Pretax Margin	-11,735.35%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovia AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-243.45%
Shareholder Yield	-243.45%
Earnings Yield	-77.65%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2